First Time Loading...

Valneva SE
NASDAQ:VALN

Watchlist Manager
Valneva SE Logo
Valneva SE
NASDAQ:VALN
Watchlist
Price: 8.5 USD -0.12% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

Valneva SE is a biotech company. [ Read More ]

The intrinsic value of one VALN stock under the Base Case scenario is 18.52 USD. Compared to the current market price of 8.5 USD, Valneva SE is Undervalued by 54%.

Key Points:
VALN Intrinsic Value
Base Case
18.52 USD
Undervaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Valneva SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VALN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Valneva SE

Provide an overview of the primary business activities
of Valneva SE.

What unique competitive advantages
does Valneva SE hold over its rivals?

What risks and challenges
does Valneva SE face in the near future?

Summarize the latest earnings call
of Valneva SE.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Valneva SE.

Provide P/S
for Valneva SE.

Provide P/E
for Valneva SE.

Provide P/OCF
for Valneva SE.

Provide P/FCFE
for Valneva SE.

Provide P/B
for Valneva SE.

Provide EV/S
for Valneva SE.

Provide EV/GP
for Valneva SE.

Provide EV/EBITDA
for Valneva SE.

Provide EV/EBIT
for Valneva SE.

Provide EV/OCF
for Valneva SE.

Provide EV/FCFF
for Valneva SE.

Provide EV/IC
for Valneva SE.

Show me price targets
for Valneva SE made by professional analysts.

What are the Revenue projections
for Valneva SE?

How accurate were the past Revenue estimates
for Valneva SE?

What are the Net Income projections
for Valneva SE?

How accurate were the past Net Income estimates
for Valneva SE?

What are the EPS projections
for Valneva SE?

How accurate were the past EPS estimates
for Valneva SE?

What are the EBIT projections
for Valneva SE?

How accurate were the past EBIT estimates
for Valneva SE?

Compare the revenue forecasts
for Valneva SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Valneva SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Valneva SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of Valneva SE compared to its peers.

Compare the P/E ratios
of Valneva SE against its peers.

Discuss the investment returns and shareholder value creation
comparing Valneva SE with its peers.

Analyze the financial leverage
of Valneva SE compared to its main competitors.

Show all profitability ratios
for Valneva SE.

Provide ROE
for Valneva SE.

Provide ROA
for Valneva SE.

Provide ROIC
for Valneva SE.

Provide ROCE
for Valneva SE.

Provide Gross Margin
for Valneva SE.

Provide Operating Margin
for Valneva SE.

Provide Net Margin
for Valneva SE.

Provide FCF Margin
for Valneva SE.

Show all solvency ratios
for Valneva SE.

Provide D/E Ratio
for Valneva SE.

Provide D/A Ratio
for Valneva SE.

Provide Interest Coverage Ratio
for Valneva SE.

Provide Altman Z-Score Ratio
for Valneva SE.

Provide Quick Ratio
for Valneva SE.

Provide Current Ratio
for Valneva SE.

Provide Cash Ratio
for Valneva SE.

What is the historical Revenue growth
over the last 5 years for Valneva SE?

What is the historical Net Income growth
over the last 5 years for Valneva SE?

What is the current Free Cash Flow
of Valneva SE?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Valneva SE

Current Assets 262.8m
Cash & Short-Term Investments 126.1m
Receivables 41.6m
Other Current Assets 95.1m
Non-Current Assets 197.2m
PP&E 156.6m
Intangibles 25.6m
Other Non-Current Assets 15.1m
Current Liabilities 158.9m
Accounts Payable 17.6m
Accrued Liabilities 42.9m
Other Current Liabilities 98.4m
Non-Current Liabilities 173m
Long-Term Debt 161.9m
Other Non-Current Liabilities 11.1m
Efficiency

Earnings Waterfall
Valneva SE

Revenue
153.7m EUR
Cost of Revenue
-100.9m EUR
Gross Profit
52.8m EUR
Operating Expenses
-134.9m EUR
Operating Income
-82.1m EUR
Other Expenses
-19.4m EUR
Net Income
-101.4m EUR

Free Cash Flow Analysis
Valneva SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

VALN Profitability Score
Profitability Due Diligence

Valneva SE's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
Positive 3-Years Revenue Growth
21/100
Profitability
Score

Valneva SE's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

VALN Solvency Score
Solvency Due Diligence

Valneva SE's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
31/100
Solvency
Score

Valneva SE's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VALN Price Targets Summary
Valneva SE

Wall Street analysts forecast VALN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VALN is 20.85 USD with a low forecast of 8.36 USD and a high forecast of 29.72 USD.

Lowest
Price Target
8.36 USD
2% Downside
Average
Price Target
20.85 USD
145% Upside
Highest
Price Target
29.72 USD
250% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

VLA Price
Valneva SE

1M 1M
+8%
6M 6M
-29%
1Y 1Y
-26%
3Y 3Y
-70%
5Y 5Y
+9%
10Y 10Y
-26%
Annual Price Range
3.79
52w Low
3.001
52w High
7.62
Price Metrics
Average Annual Return 75.7%
Standard Deviation of Annual Returns 145.06%
Max Drawdown -89%
Shares Statistics
Market Capitalization 557.4m EUR
Shares Outstanding 138 788 000
Percentage of Shares Shorted
N/A

VLA Return Decomposition
Main factors of price return

What is price return decomposition?

VALN News

Last Important Events
Valneva SE

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Valneva SE

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Valneva SE Logo
Valneva SE

Country

France

Industry

Biotechnology

Market Cap

557.4m USD

Dividend Yield

0%

Description

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Contact

PAYS DE LA LOIRE
Saint-Herblain
6 rue Alain Bombard
+33228073710.0
https://valneva.com/

IPO

2007-06-28

Employees

722

Officers

President, CEO & Director
Mr. Thomas Lingelbach
Chief Financial Officer
Mr. Peter Buhler
Chief Business Officer
Mr. Franck Grimaud MBA
Chief Medical Officer
Dr. Juan-Carlos Jaramillo M.D.
Chief Commercial Officer
Ms. Dipal Patel
Vice President of Investor Relations
Mr. Joshua Drumm Ph.D.
Show More
VP of Global Communications & European Investor Relations
Ms. Laetitia Bachelot-Fontaine
Head of Global Medical Affairs
Mr. Christian Taucher
Head of Clinical Operations
Ms. Susanne Eder-Lingelbach
VP & Program Director of Chikungunya Vaccine
Katrin Dubischar
Show Less

See Also

Discover More
What is the Intrinsic Value of one VALN stock?

The intrinsic value of one VALN stock under the Base Case scenario is 18.52 USD.

Is VALN stock undervalued or overvalued?

Compared to the current market price of 8.5 USD, Valneva SE is Undervalued by 54%.